<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study

<i>KRAS</i> mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer. However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation is the most...

Descripción completa

Detalles Bibliográficos

Autores principales:	Nuria Garcia-Carbonero, Javier Martinez-Useros, Weiyao Li, Alberto Orta, Nuria Perez, Cristina Carames, Tatiana Hernandez, Irene Moreno, Gloria Serrano, Jesus Garcia-Foncillas
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2020-01-01
Colección:	Cells
Materias:	<i>kras</i> <i>braf</i> metastatic colorectal cancer prognosis chemotherapy anti-egfr biomarker
Acceso en línea:	https://www.mdpi.com/2073-4409/9/1/219
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!